JP2014512171A - コロイデレミアの遺伝子治療に使用するためのａａｖベクター - Google Patents

コロイデレミアの遺伝子治療に使用するためのａａｖベクター Download PDF

Info

Publication number
JP2014512171A
JP2014512171A JP2013554938A JP2013554938A JP2014512171A JP 2014512171 A JP2014512171 A JP 2014512171A JP 2013554938 A JP2013554938 A JP 2013554938A JP 2013554938 A JP2013554938 A JP 2013554938A JP 2014512171 A JP2014512171 A JP 2014512171A
Authority
JP
Japan
Prior art keywords
vector
aav
rep1
sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013554938A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014512171A5 (enExample
Inventor
マクラーレン、ロバート
シーブラ、ミゲル
ジョン デュアリング、マシュウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ISISINNOVATION LIMITED
Original Assignee
ISISINNOVATION LIMITED
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43881504&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2014512171(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ISISINNOVATION LIMITED filed Critical ISISINNOVATION LIMITED
Publication of JP2014512171A publication Critical patent/JP2014512171A/ja
Publication of JP2014512171A5 publication Critical patent/JP2014512171A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2013554938A 2011-02-22 2012-02-21 コロイデレミアの遺伝子治療に使用するためのａａｖベクター Pending JP2014512171A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1103062.4 2011-02-22
GBGB1103062.4A GB201103062D0 (en) 2011-02-22 2011-02-22 Method
PCT/GB2012/050376 WO2012114090A1 (en) 2011-02-22 2012-02-21 Aav -vectors for use in gene therapy of choroideremia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017117286A Division JP2017221192A (ja) 2011-02-22 2017-06-14 コロイデレミアの遺伝子治療に使用するためのａａｖベクター

Publications (2)

Publication Number Publication Date
JP2014512171A true JP2014512171A (ja) 2014-05-22
JP2014512171A5 JP2014512171A5 (enExample) 2015-04-16

Family

ID=43881504

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013554938A Pending JP2014512171A (ja) 2011-02-22 2012-02-21 コロイデレミアの遺伝子治療に使用するためのａａｖベクター
JP2017117286A Pending JP2017221192A (ja) 2011-02-22 2017-06-14 コロイデレミアの遺伝子治療に使用するためのａａｖベクター
JP2019201092A Pending JP2020054345A (ja) 2011-02-22 2019-11-05 コロイデレミアの遺伝子治療に使用するためのａａｖベクター
JP2022193831A Pending JP2023036618A (ja) 2011-02-22 2022-12-02 コロイデレミアの遺伝子治療に使用するためのａａｖベクター

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017117286A Pending JP2017221192A (ja) 2011-02-22 2017-06-14 コロイデレミアの遺伝子治療に使用するためのａａｖベクター
JP2019201092A Pending JP2020054345A (ja) 2011-02-22 2019-11-05 コロイデレミアの遺伝子治療に使用するためのａａｖベクター
JP2022193831A Pending JP2023036618A (ja) 2011-02-22 2022-12-02 コロイデレミアの遺伝子治療に使用するためのａａｖベクター

Country Status (18)

Country Link
US (4) US9834788B2 (enExample)
EP (2) EP2678435B2 (enExample)
JP (4) JP2014512171A (enExample)
KR (3) KR102299430B1 (enExample)
CN (2) CN107881198A (enExample)
AU (2) AU2012220404B2 (enExample)
BR (1) BR112013021318B1 (enExample)
CA (1) CA2827975C (enExample)
DK (1) DK2678435T3 (enExample)
ES (1) ES2676550T5 (enExample)
GB (1) GB201103062D0 (enExample)
HK (2) HK1258917A1 (enExample)
IL (1) IL228031B (enExample)
MX (2) MX356525B (enExample)
PL (1) PL2678435T3 (enExample)
PT (1) PT2678435T (enExample)
SG (1) SG192911A1 (enExample)
WO (1) WO2012114090A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018511652A (ja) * 2015-03-06 2018-04-26 マサチューセッツ アイ アンド イヤー インファーマリー Ｐｒｐｆ３１遺伝子における変異により引き起こされる遺伝性網膜変性に対する遺伝子増強療法
JP2019502378A (ja) * 2015-12-14 2019-01-31 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 眼疾患のための遺伝子療法
JP2019509762A (ja) * 2016-03-10 2019-04-11 ナイトスタアールエックス リミテッド プレニル化アッセイ
JP2021505619A (ja) * 2017-12-06 2021-02-18 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 発作障害の治療におけるｍｉｒ１０１またはｍｉｒ１２８の使用
JP2021520233A (ja) * 2018-04-05 2021-08-19 ナイトスター リミテッド Ａａｖ組成物、作製する方法及び使用の方法

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201103062D0 (en) † 2011-02-22 2011-04-06 Isis Innovation Method
CN105980569A (zh) 2013-08-05 2016-09-28 莱顿大学医学中心附属莱顿教学医院 重组aav-crumbs同源物组合物及治疗lca-8和进行性rp的方法
KR102281881B1 (ko) * 2013-12-06 2021-07-27 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름) 대상체의 망막 색소 상피에서 목적 폴리뉴클레오티드를 발현시키기 위한 방법 및 약학적 조성물
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
EP3215191B1 (en) 2014-11-05 2024-08-14 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US10584337B2 (en) 2016-05-18 2020-03-10 Voyager Therapeutics, Inc. Modulatory polynucleotides
IL297576B2 (en) 2016-05-18 2024-02-01 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
EP3831281B1 (en) 2016-08-30 2026-02-25 The Regents of The University of California Devices and systems for biomedical targeting and delivery
US10633689B2 (en) 2016-11-07 2020-04-28 Spark Therapeutics, Inc. Rab Escort Protein potency assay
US11938197B2 (en) * 2017-01-10 2024-03-26 The Sydney Children's Hospitals Network (Randwick And Westmead (Incorporating The Royal Alexandra Hospital For Children) Polynucleotides and vectors for the expression of transgenes
US10550405B2 (en) 2017-03-15 2020-02-04 The University Of North Carolina At Chapel Hill Rational polyploid adeno-associated virus vectors and methods of making and using the same
MX2019013172A (es) 2017-05-05 2020-09-07 Voyager Therapeutics Inc Composiciones y metodos para tratar la enfermedad de huntington.
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
US11827898B2 (en) 2017-06-14 2023-11-28 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
US11512327B2 (en) 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
MX2020004005A (es) * 2017-10-03 2020-10-05 Prevail Therapeutics Inc Terapias genicas para los trastornos lisosomales.
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
AU2018352986A1 (en) 2017-10-17 2020-05-14 Nightstarx Limited Prenylation assay
WO2019152841A1 (en) 2018-02-01 2019-08-08 Homology Medicines, Inc. Adeno-associated virus compositions for pah gene transfer and methods of use thereof
AU2019215152A1 (en) 2018-02-01 2020-08-20 Homology Medicines, Inc. Adeno-associated virus compositions for restoring PAH gene function and methods of use thereof
US11306329B2 (en) 2018-02-19 2022-04-19 City Of Hope Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof
AU2018422759B2 (en) * 2018-05-07 2026-01-22 The University Of North Carolina At Chapel Hill Rational polyploid adeno-associated virus vectors and methods of making and using the same
CN112424359A (zh) 2018-05-15 2021-02-26 沃雅戈治疗公司 用于治疗帕金森氏病的组合物和方法
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
US20220193261A1 (en) * 2019-04-30 2022-06-23 The Trustees Of The University Of Pennsylvania Compositions useful for treatment of pompe disease
TW202140791A (zh) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
TW202208632A (zh) 2020-05-27 2022-03-01 美商同源醫藥公司 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
IL300526A (en) 2020-08-17 2023-04-01 Massachusetts Inst Technology Approaches to SHANK3 gene therapy
WO2022109247A1 (en) 2020-11-20 2022-05-27 Biogen Ma Inc. Viral vector potency assay
EP4482970A1 (en) 2022-02-23 2025-01-01 Massachusetts Institute of Technology Methods for upregulating shank3 expression
JP2025528188A (ja) 2022-08-11 2025-08-26 インスティテュート オブ モレキュラー アンド クリニカル オフサルモロジー バーゼル （アイオービー） ヒト錐体光受容体オプトジェネティクス構築物
AU2023323327A1 (en) 2022-08-11 2025-02-13 Institute Of Molecular And Clinical Ophthalmology Basel (Iob) Promoters for specific expression of genes in cone photoreceptors
CN121794288A (zh) 2023-05-05 2026-04-03 麻省理工学院 Shank3基因治疗方法
WO2025090942A1 (en) * 2023-10-26 2025-05-01 University Of Notre Dame Du Lac Gene therapy for treatment of neurometabolic disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003526377A (ja) * 2000-03-14 2003-09-09 ニユーロロジクス・インコーポレーテツド キメラキャプシドベクターの製造
WO2004084951A2 (en) * 2003-03-28 2004-10-07 Universite De Nantes A method and vectors for selectively transducing retinal pigment epithelium cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0856585A1 (en) 1997-01-29 1998-08-05 Introgene B.V. A conditional replication and expression system
CA2442670A1 (en) * 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
WO2006090689A1 (ja) * 2005-02-23 2006-08-31 Dnavec Corporation Siv-pedfベクターを用いた眼組織細胞におけるアポトーシス変性を伴う疾患の治療薬
AU2006242371A1 (en) * 2005-04-29 2006-11-09 The University Of North Carolina At Chapel Hill Methods and compositions for regulated expression of nucleic acid at post-transcriptional level
US20090022731A1 (en) * 2006-08-25 2009-01-22 Wyeth Arthritis-associated B cell gene expression
US20100278843A1 (en) * 2007-08-16 2010-11-04 St. Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
EP2242840B1 (en) * 2008-01-29 2019-07-24 Applied Genetic Technologies Corporation Recombinant adeno-associated virus production using bhk cells in suspension
CA2713755A1 (en) * 2008-02-07 2009-08-13 Ceregene, Inc. Rescue of photoreceptors by intravitreal administration of an expression vector encoding a therapeutic protein
SI3988660T1 (sl) * 2009-05-02 2025-09-30 Genzyme Corporation Genska terapija za nevrodegenerativne motnje
US9169494B2 (en) 2010-01-12 2015-10-27 The University Of North Carolina At Chapel Hill Restrictive inverted terminal repeats for viral vectors
GB201103062D0 (en) † 2011-02-22 2011-04-06 Isis Innovation Method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003526377A (ja) * 2000-03-14 2003-09-09 ニユーロロジクス・インコーポレーテツド キメラキャプシドベクターの製造
WO2004084951A2 (en) * 2003-03-28 2004-10-07 Universite De Nantes A method and vectors for selectively transducing retinal pigment epithelium cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 51, no. 10, JPN6017034827, 2010, pages 4913 - 4920, ISSN: 0003640615 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018511652A (ja) * 2015-03-06 2018-04-26 マサチューセッツ アイ アンド イヤー インファーマリー Ｐｒｐｆ３１遺伝子における変異により引き起こされる遺伝性網膜変性に対する遺伝子増強療法
JP2021059561A (ja) * 2015-03-06 2021-04-15 マサチューセッツ アイ アンド イヤー インファーマリー Ｐｒｐｆ３１遺伝子における変異により引き起こされる遺伝性網膜変性に対する遺伝子増強療法
JP7239550B2 (ja) 2015-03-06 2023-03-14 マサチューセッツ アイ アンド イヤー インファーマリー Ｐｒｐｆ３１遺伝子における変異により引き起こされる遺伝性網膜変性に対する遺伝子増強療法
JP2023071867A (ja) * 2015-03-06 2023-05-23 マサチューセッツ アイ アンド イヤー インファーマリー Ｐｒｐｆ３１遺伝子における変異により引き起こされる遺伝性網膜変性に対する遺伝子増強療法
JP2019502378A (ja) * 2015-12-14 2019-01-31 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 眼疾患のための遺伝子療法
JP7057281B2 (ja) 2015-12-14 2022-04-19 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 眼疾患のための遺伝子療法
JP2022088656A (ja) * 2015-12-14 2022-06-14 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 眼疾患のための遺伝子療法
JP7878917B2 (ja) 2015-12-14 2026-06-23 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 眼疾患のための遺伝子療法
JP2019509762A (ja) * 2016-03-10 2019-04-11 ナイトスタアールエックス リミテッド プレニル化アッセイ
JP7021122B2 (ja) 2016-03-10 2022-02-16 ナイトスタアールエックス リミテッド プレニル化アッセイ
JP2021505619A (ja) * 2017-12-06 2021-02-18 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 発作障害の治療におけるｍｉｒ１０１またはｍｉｒ１２８の使用
JP2021520233A (ja) * 2018-04-05 2021-08-19 ナイトスター リミテッド Ａａｖ組成物、作製する方法及び使用の方法

Also Published As

Publication number Publication date
CA2827975A1 (en) 2012-08-30
US20140107185A1 (en) 2014-04-17
WO2012114090A1 (en) 2012-08-30
CN103562396A (zh) 2014-02-05
PL2678435T3 (pl) 2018-11-30
EP2678435A1 (en) 2014-01-01
EP2678435B2 (en) 2024-02-07
US20230332176A1 (en) 2023-10-19
BR112013021318B1 (pt) 2021-12-07
ES2676550T5 (es) 2024-06-27
US20180135078A1 (en) 2018-05-17
MX2013009604A (es) 2013-09-16
MX388146B (es) 2025-03-19
KR20210112407A (ko) 2021-09-14
KR102299430B1 (ko) 2021-09-07
JP2023036618A (ja) 2023-03-14
IL228031A0 (en) 2013-09-30
DK2678435T3 (en) 2018-08-27
KR102139203B1 (ko) 2020-07-29
SG192911A1 (en) 2013-09-30
BR112013021318A2 (pt) 2016-10-25
EP3428283A1 (en) 2019-01-16
IL228031B (en) 2018-02-28
GB201103062D0 (en) 2011-04-06
CA2827975C (en) 2023-06-13
AU2012220404B2 (en) 2017-04-20
CN107881198A (zh) 2018-04-06
KR20140044793A (ko) 2014-04-15
HK1258917A1 (en) 2019-11-22
US9834788B2 (en) 2017-12-05
HK1249548A1 (zh) 2018-11-02
AU2012220404A1 (en) 2013-09-12
PT2678435T (pt) 2018-07-17
JP2020054345A (ja) 2020-04-09
EP2678435B1 (en) 2018-05-16
MX356525B (es) 2018-06-01
KR20200092422A (ko) 2020-08-03
AU2017206254A1 (en) 2017-08-10
ES2676550T3 (es) 2018-07-20
JP2017221192A (ja) 2017-12-21
US20210032656A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
US20230332176A1 (en) Aav-vectors for use in gene therapy of choroideremia
US11072803B2 (en) Hybrid dual recombinant AAV vector systems for gene therapy
US12377169B2 (en) Dual AAV-MYO7A vectors with improved safety for the treatment of USH1B
US20250049949A1 (en) Gene therapy for lamin a-associated deficiencies
EP4444892A2 (en) Junctophilin-2 (jph2) gene therapy using aav vector
HK1191672A (en) Aav-vectors for use in gene therapy of choroideremia
HK1191672B (en) Aav-vectors for use in gene therapy of choroideremia
HK1194982B (en) Adeno-associated virus virions with variant capsid and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160707

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170615

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170706

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20170915

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20180314